FLCN and metabolic dysfunction-associated steatotic liver disease: In a recent study, Gosis and colleagues reported that selective inhibition of mTORC1, through the deletion of the RagC/D guanosine triphosphatase-activating protein folliculin (FLCN), protects against NAFLD and NASH [115].